Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538968 | 0.91 | LTA4H (0.39) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042424 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042428 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042227 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042426 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28106834 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042226 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042470 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042429 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL2165677 | 0.88 | CASR (0.36) | NPC1RAB9ASMN1; SMN2LTA4HLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | NPC1 1607/4885RAB9A 3674/4885SMN1; SMN2 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.